The invention relates to the field of traditional Chinese medicines, in particular to a
traditional Chinese medicine for treating pulmonary arterial hypertension, and effectively solves the problems that the
western medicine for treating pulmonary arterial hypertension is limited in
curative effect of
symptomatic treatment and has many side effects, targeted treatment cannot fundamentally prevent the progress of a
disease course and is poor in prognosis, and invasive treatment is relatively large in damage to a body, general in prognosis and high in price. According to the technical scheme, concentrated watered pills are prepared from the following raw medicinal materials by weight: 108 to 132g of
astragalus membranaceus, 10 to 20g of bighead atractylodes
rhizome, 27 to 33g of
rhodiola rosea, 10 to 20g of
trichosanthes kirilowii maxim, 27 to 33g of
allium macrostemon, 10 to 20g of rhizoma pinellinae praeparata, 27 to 33g of
salvia miltiorrhiza, 9 to 11g of safflower, 2.7 to 3.3 g of pseudo-
ginseng, 27 to 33g of
semen lepidii, 27 to 33g of
white mulberry root-
bark, 27 to 33g of parasitic
loranthus, 45 to 55g of crude dragon bone, 45 to 55g of raw
oyster shell, 54 to 66g of
kudzu vine root, 45 to 55g of poria cocos, 45 to 55g of
coix seed, 27 to 33g of
earthworm and 9 to 11g of According to the treatment principle of tonifying qi, reducing
phlegm, removing
blood stasis and inducing
diuresis, the
traditional Chinese medicine composition can stably, durably and effectively control pulmonary arterial hypertension, improve the
right heart function and control
disease progression, and the
life quality of patients is fundamentally improved.